Regulus Therapeutics Inc logo

Regulus Therapeutics Inc

NAS:RGLS (USA)  
$ 2.27 +0.05 (+2.25%) 10:09 PM EST
At Loss
P/B:
2.16
Market Cap:
$ 148.61M
Enterprise V:
$ 123.96M
Volume:
97.80K
Avg Vol (2M):
4.58M
Also Trade In:
Volume:
97.80K
At Loss
Avg Vol (2M):
4.58M

Business Description

Description
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Name Current Vs Industry Vs History
Cash-To-Debt 9.95
Equity-to-Asset 0.69
Debt-to-Equity 0.11
Debt-to-EBITDA -0.08
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 40.61
9-Day RSI 40.75
14-Day RSI 45.57
6-1 Month Momentum % 107.35
12-1 Month Momentum % 107.35

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.31
Quick Ratio 3.31
Cash Ratio 2.79

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -44.2
Shareholder Yield % -8.59